In 63 adults with severe fibromyalgia, weekly rozanolixizumab improved BPI-SF pain interference at 12 weeks by only 0·5 points more than placebo, meeting the pre-specified one-sided 10% threshold but not significant at two-sided 5% (p=0·13). No serious adverse events on drug.
RCTn = 63
Goebel et al. Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial